latest news releases from the newsroom
Nicodrops Inc. Announces New Director Of Sales To Advisory Board
LA MESA, Calif., Dec. 9, 2004 (PRIMEZONE) -- Nicodrops, Inc. (Pink Sheets:NCDP), developer of the world's first drug-free, non-nicotine smoking cessation lozenge, announced that they have selected Joel Appel, best known for his work with Ultra Slim-Fast, as new Director of Sales and marketing for NCDP. Mr. Appel will also sit on the Nicodrops Advisory Board. Mr. Appel was selected not only for his reputation in the industry for putting Slim-Fast on the map but his vast knowledge of product placement and advertising to maximize all markets. To date, Mr. Appel has been working as a consultant for a number of mainstream retail-oriented products.
Corporate Mortgage Solutions Inc.
National Hospitality Group Begins Trading with 3000 New Shareholders
ST. PETERSBURG, Fla., Dec. 9, 2004 (PRIMEZONE) -- National Hospitality Group, Inc. (Pink Sheets:NHGP) is pleased to announce that it has begun trading under the symbol of NHGP with 3000 new shareholders. On November 15, 2004, Prime Rate Investors Inc. shareholders were issued restricted shares of National Hospitality Group, Inc. (Pink Sheets:NHGP) common stock. These shares were distributed in the spin-off of NHGP and are restricted for 12 months and have been distributed to the relevant brokerage firms on the 15th November 2004.
Myriad Genetics Files IND For Drug Candidate From Compound Family Licensed From Maxim Pharmaceuiticals
STOCKHOLM, Sweden and SAN DIEGO, Dec. 9, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND) application with the FDA for a Phase 1 clinical study of MPC-6827, a pro-apoptotic cancer therapeutic candidate identified by Myriad researchers from a family of compounds licensed from Maxim. The study is designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors in an escalating dose regimen. This compound family was discovered by Maxim through its proprietary live cell high-throughput caspase-3 screening technology. In pre-clinical studies, MPC-6827 demonstrated activity that was better than control using current standard-of-care chemotherapy drug in xenograft models of breast, pancreas, colon, ovary and prostate cancers.
Allied Irish Banks, p.l.c.
Allied Irish Banks, p.l.c. Trading Update
DUBLIN, Ireland, Dec. 9, 2004 (PRIMEZONE) -- Allied Irish Banks, p.l.c. ("AIB") (NYSE:AIB) is issuing the following update on trading before its year end close period. Our performance in 2004 is strong. We are comfortable with market analysts' consensus forecast of 125c in adjusted earnings per share for 2004, relative to the comparable base of 118c in 2003.We occupy prime positions in economies characterised by relatively high growth rates, providing a favourable platform for us to sustain and grow our profits. Our business pipelines reflect a positive outlook and underpin our confidence that current momentum will be maintained. We continue to expect double digit aggregate profit growth in constant currency from our operating divisions this year. We expect to maintain a clear positive gap between income and cost growth and a consequent reduction in our cost / income ratio. M&T continues to perform very well and the profit contribution from this investment, in dollar terms, is also anticipated to show a double digit annual increase. As indicated at the interim stage, we expect an adverse currency translation impact of around 4% after hedging. Other offsetting factors to group earnings continue to be a higher effective tax rate due to geographic profit mix and Polish minorities. Our capital and funding positions are prudent and we are actively managing both to support future profitable growth and optimise returns.